Biotin-targeted Pluronic® P123/F127 mixed micelles delivering niclosamide: A repositioning strategy to treat drug-resistant lung cancer cells

Annapina Russo, Diogo Silva Pellosi, Valentina Pagliara, Maria Rita Milone, Biagio Pucci, Wilker Caetano, Noboru Hioka, Alfredo Budillon, Francesca Ungaro, Giulia Russo, Fabiana Quaglia

Research output: Contribution to journalArticle


With the aim to develop alternative therapeutic tools for the treatment of resistant cancers, here we propose targeted Pluronic® P123/F127 mixed micelles (PMM) delivering niclosamide (NCL) as a repositioning strategy to treat multidrug resistant non-small lung cancer cell lines. To build multifunctional PMM for targeting and imaging, Pluronic® F127 was conjugated with biotin, while Pluronic® P123 was fluorescently tagged with rhodamine B, in both cases at one of the two hydroxyl end groups. This design intended to avoid any interference of rhodamine B on biotin exposition on PMM surface, which is a key fundamental for cell trafficking studies. Biotin-decorated PMM were internalized more efficiently than non-targeted PMM in A549 lung cancer cells, while very low internalization was found in NHI3T3 normal fibroblasts. Biotin-decorated PMM entrapped NCL with good efficiency, displayed sustained drug release in protein-rich media and improved cytotoxicity in A549 cells as compared to free NCL (P 

Original languageEnglish
Pages (from-to)127-139
Number of pages13
JournalInternational Journal of Pharmaceutics
Issue number1
Publication statusPublished - Sep 10 2016



  • Lung cancer cells
  • Micelle
  • Multidrug resistance
  • Niclosamide
  • Pluronic

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this